Literature DB >> 18283394

Clinical characteristics of patients with late-onset multiple sclerosis.

Bernhard Kis1, Bastian Rumberg, Peter Berlit.   

Abstract

We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group - the oldest patient was 82 - and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p < 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283394     DOI: 10.1007/s00415-008-0778-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Progressive forms of MS: classification streamlined or consensus overturned?

Authors:  B G Weinshenker
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

2.  [Multiple sclerosis: descriptive study of its clinical forms in 302 cases].

Authors:  M A Moreira; E Felipe; M F Mendes; C P Tilbery
Journal:  Arq Neuropsiquiatr       Date:  2000-06       Impact factor: 1.420

3.  Infections and the risk of relapse in multiple sclerosis.

Authors:  Christian Confavreux
Journal:  Brain       Date:  2002-05       Impact factor: 13.501

4.  CLINICAL STUDIES OF MULTIPLE SCLEROSIS IN ISRAEL. 3. CLINICAL COURSE AND PROGNOSIS RELATED TO AGE AT ONSET.

Authors:  U LEIBOWITZ; M ALTER; L HALPERN
Journal:  Neurology       Date:  1964-10       Impact factor: 9.910

Review 5.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

6.  Features of multiple sclerosis in older patients in South Wales.

Authors:  A D White; R J Swingler; D A Compston
Journal:  Gerontology       Date:  1990       Impact factor: 5.140

Review 7.  Clinical trials in multiple sclerosis.

Authors:  J H Noseworthy
Journal:  Curr Opin Neurol Neurosurg       Date:  1993-04

8.  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.

Authors:  S A Hawkins; G V McDonnell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

9.  Multiple sclerosis after age 50.

Authors:  J Noseworthy; D Paty; T Wonnacott; T Feasby; G Ebers
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  20 in total

Review 1.  Menopause in multiple sclerosis: therapeutic considerations.

Authors:  Riley Bove; Tanuja Chitnis; Maria Houtchens
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

Review 2.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

3.  Primary central nervous system vasculitis: clinical experiences with 21 new European cases.

Authors:  Markus Kraemer; Peter Berlit
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

4.  Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly.

Authors:  W Oliver Tobin; Chiara Costanzi; Yong Guo; Joseph E Parisi; Stephen D Weigand; Claudia F Lucchinetti
Journal:  Mult Scler       Date:  2016-10-19       Impact factor: 6.312

5.  Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.

Authors:  Rachel Butler Pagnotti; Le H Hua; Justin B Miller
Journal:  Mult Scler       Date:  2021-08-19       Impact factor: 5.855

Review 6.  Autoimmune diseases and reproductive aging.

Authors:  Riley Bove
Journal:  Clin Immunol       Date:  2013-02-28       Impact factor: 3.969

7.  Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum.

Authors:  Angela Groebe; Tim Clarner; Werner Baumgartner; Jon Dang; Cordian Beyer; Markus Kipp
Journal:  Cerebellum       Date:  2009-03-04       Impact factor: 3.847

8.  No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50.

Authors:  Riley Bove; Alexander Musallam; Brian C Healy; Maria Houtchens; Bonnie I Glanz; Samia Khoury; Charles R Guttmann; Philip L De Jager; Tanuja Chitnis
Journal:  BMC Neurol       Date:  2013-07-03       Impact factor: 2.474

9.  How does age at onset influence the outcome of autoimmune diseases?

Authors:  Manuel J Amador-Patarroyo; Alberto Rodriguez-Rodriguez; Gladis Montoya-Ortiz
Journal:  Autoimmune Dis       Date:  2011-12-13

10.  A case of late-onset multiple sclerosis mimicking glioblastoma and displaying intraoperative 5-aminolevulinic acid fluorescence.

Authors:  U Nestler; A Warter; P Cabre; N Manzo
Journal:  Acta Neurochir (Wien)       Date:  2012-03-09       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.